Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro.
Mohsin
M
Shah
Paolo
P
Gallipoli
John
J
Lyons
Tessa
T
Holyoake
Heather
H
Jørgensen
D000970:Antineoplastic Agents / Q000494:pharmacology*; D064127:Aurora Kinases; D001549:Benzamides; D001562:Benzimidazoles / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D006801:Humans; D000068877:Imatinib Mesylate; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000201:enzymology*; D010879:Piperazines / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000494:pharmacology*; D014508:Urea / Q000031:analogs & derivatives* / Q000494:pharmacology
C535237:1-cyclopropyl-3-(3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl)urea; D000970:Antineoplastic Agents; D001549:Benzamides; D001562:Benzimidazoles; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D014508:Urea; D053612:Janus Kinases; D064127:Aurora Kinases; D017346:Protein Serine-Threonine Kinases